In the week ending Friday 21 August 2026, a sell off across sovereign bond markets pushed US 30 year yields to their highest level since 2007 and dragged every major US index into the red. Yet this ASX market update August 2026 is not really about bonds. It is about two healthcare results, reported three days apart, that the market rewarded for opposite reasons. CSL rose 23.3% on a statutory loss. Moderna rose more than 100% in a single session on a clinical trial result carrying no revenue at all.
Global markets
The S&P 500 finished the week at 7,674.31, down 1.4%, its first weekly loss since late July. Information technology shed more than 3% as higher Treasury yields pressured long duration assets, and a firm Friday was not enough to rescue the week.
| US Markets | % Change | Rest of the World | % Change |
|---|---|---|---|
| The Dow Jones | -0.8% | Hang Seng | +3.6% |
| S&P 500 | -1.4% | STOXX Europe 600 | -0.4% |
| Nasdaq | -2.1% | Nikkei 225 | -3.9% |
The standout was Moderna. Its mRNA cancer vaccine with Merck, intismeran autogene, met its primary and key secondary endpoints in the Phase 3 INTerpath-001 melanoma trial, the first positive late stage result for an mRNA based cancer therapy. Shares closed Wednesday 125.9% higher, having traded as much as 177% up intraday, the stock’s best day on record. The move added roughly US$32.8 billion of market value across three sessions and cost short sellers US$5.5 billion.
Elsewhere the picture was rotation rather than conviction. Japan’s Nikkei 225 gave up 3.9% to 66,016.36 as domestic inflation pressure and global yields bit, breaking a two week winning streak. Europe’s STOXX 600 drifted 0.4% lower. Hong Kong ran the other way, the Hang Seng adding 3.6% to 26,009.46. Gold climbed above US$4,600 an ounce, its highest since mid May and a third consecutive weekly gain, while Brent crude added more than 5% to near US$94 as Washington moved to economically isolate Iran.
The ASX
The ASX 200 closed at 9,058.9, down 0.6% for the week. That is a shallow decline concealing an unusually violent week underneath it. The index fell in nine of the last eleven sessions, yet gave back only half the 5.5% run up between 24 July and 6 August.
| Best 3 Movers | % Change | Worst 3 Movers | % Change |
|---|---|---|---|
| CSL | +23.3% | IRE | -20.0% |
| OBM | +23.3% | JBH | -15.3% |
| RWC | +20.2% | MP1 | -14.4% |
Real estate, retailers and technology carried the damage. Financials lost 9.0% across eleven sessions as bank results pointed to mortgage application volumes down 10% to 15% post budget, and WiseTech fell hard after disclosing an ACCC search warrant on Wednesday. Healthcare went the other way entirely, rallying 12.1% over three sessions before a 1.5% breather on Friday.
CSL delivered its best single session in more than two decades on Tuesday, rising 16.4%, and finished the week 23.3% higher. The result was a statutory net loss of US$2.6 billion, driven by US$7.1 billion of impairments and US$799 million of restructuring costs, none of it cash. Revenue was US$15.8 billion, underlying NPATA US$3.1 billion, operating cash flow US$3.5 billion, and FY27 guidance points to roughly 5% underlying profit growth. Ora Banda matched CSL’s gain on the strength of the gold complex, and Reliance Worldwide added 20.2%. At the other end IRESS fell 20.0%, JB Hi-Fi 15.3% and Megaport 14.4%.
The Reserve Bank did not meet this week. The cash rate remains at 4.35% following the unanimous hold on 11 August, with the next decision due 28 and 29 September. July employment fell 15,800 and unemployment edged up to 4.5%.
Why the market paid for two opposite things
Two healthcare results defined this week and they were priced on opposite logic. That contrast is worth more than either result on its own.
CSL’s rally was not about the loss. It was about the impairments being non cash and operating cash flow holding at US$3.5 billion, down just 1% year on year. Investors read past a US$2.6 billion headline to the arithmetic underneath it, then repriced a business that had endured a 48% drawdown and now sits down only 1.7% for the calendar year. That is the market re establishing what it will pay for cash flows it can already see.
Moderna was the reverse. A stock down roughly 90% from its Covid peak, heavily shorted, where a single binary outcome went the right way. The result is genuinely significant: it is the first time an mRNA cancer therapy has cleared Phase 3. But the stock now trades around 70% above the average analyst target, which tells you the price has moved well ahead of anything that can be modelled. That is the market discovering an optionality it had written off. Both moves are rational. Only one of them is repeatable.
The wider week made the same point more quietly. Long bond yields at 2007 levels set the discount rate under every long duration asset in the world, and they are increasingly being set by the volume of government issuance rather than by inflation expectations. That is the cleanest explanation for why this market keeps rewarding earnings that arrive soon over earnings that arrive eventually.
The practical translation is not complicated. If you hold the Moderna style of exposure, size it as the lottery ticket it is. If you hold the CSL style, read the cash flow statement rather than the headline. And be paid properly for the time you are asked to wait, which is why we keep our private market and income strategies weighted toward contracted cash flows.
Book a strategy call at barkerwealth.com.au to talk through how this week’s rotation sits against your own positioning. You can also read last week’s market update or more about how we work with wholesale investors.
This commentary is intended for general information only and does not constitute personal financial advice. You should consider your own objectives, financial situation and needs before making any investment decisions. Barker Wealth Management Pty Ltd ABN 46 695 875 962, trading as Barker Wealth, holds Australian Financial Services Licence (AFSL) 700297. Your adviser is Joshua Barker (AR 1274752).